The highly collaborative and friendly nature of the thoracic oncology community is not accidental. It was forged from the 'shared trauma' of consistently losing patients to lung cancer in the past, creating a strong bond and collective drive to find better treatments together rather than in competition.

Instead of viewing other T-cell engager companies as direct competitors, Kevin Pojasek refers to them as "peer companies." This collaborative mindset recognizes that in a nascent field, multiple players help validate the therapeutic approach for investors and pharma, ultimately growing the entire market. They compete on specific targets, not by tearing each other down.

To humanize R&D and maintain motivation, biotech leaders bring patients into the company. This practice directly connects scientists with the human impact of their work, grounding the entire team in their shared purpose, especially on difficult days.

Contrary to the expectation of fierce rivalry, startups in crowded spaces like voice AI within the same YC batch often form collaborative groups. They share learnings on common technical hurdles, turning potential competition into a support system.

Luba Greenwood reframes competition in biotech as a positive force. When multiple companies pursue the same biological target, it validates the target's importance and accelerates discovery. This collaborative mindset benefits the entire field and, ultimately, patients, as the best and safest drug will prevail.

Successful biotech teams are built on four pillars: genuine scientific curiosity, professional integrity to face data honestly (avoiding your own "Kool-Aid"), the ability to connect science to viable business outcomes, and a low-friction human environment free from politics and drama, which is the ultimate driver.

Benchmark's unconventional structure, where all partners have equal equity and power, aligns incentives for collaboration. Instead of the 'sharp elbow' culture of hierarchical firms, this model ensures senior partners are motivated to mentor and support junior members, as everyone shares equally in their success.

Developing a new medicine is 'the toughest team sport,' requiring hundreds of people across diverse disciplines over many years. In this context, culture isn't a perk; it's the fundamental 'glue' that enables these disparate teams to work in concert and succeed. Without it, even the best individual players will fail.

The most valuable board directors go beyond fiduciary oversight and serve as a confidential peer and sounding board for the CEO. This relationship is crucial in a role that often lacks internal peers for strategic counsel.